Seedlabs

SOFA-2 Trial Kit: Standardized Cross-Site Scoring for Sepsis Trial Eligibility and Endpoints

A tool for clinical trials to ensure sepsis is scored exactly the same way across different hospitals.

An eSource module for clinical trials that computes SOFA-2 identically at every study site — for SOFA-based inclusion criteria and day-1-to-day-7 organ-dysfunction endpoints — with a regulator-ready audit trail, so multicenter critical-care trials stop adding scoring noise between sites.

MedicineSepsis Diagnosis and Treatment
Microbial Symbiosis and ResistancePharmaceutical clinical trials — sepsis and critical-care study eligibility and endpoint scoring for CROs and sponsors

Concept

Sepsis and critical-care trials routinely use SOFA-based inclusion criteria (a minimum organ-dysfunction score) and sequential SOFA change as an efficacy or safety endpoint. Today each site typically scores by hand or with local, outdated SOFA-1 logic, so two sites can score the same patient differently — noise that dilutes eligibility enrichment and endpoint power. This product is a standardized scoring kit: a module that pulls each site's EHR/lab data, computes SOFA-2 with identical logic everywhere, timestamps every component, and pushes auditable day-1-to-day-7 scores into the trial's eCRF. The single wedge is one consistent, inspectable organ-dysfunction score across all sites in a study. Because SOFA-2 was developed and validated across 9 countries spanning high- and low-resource ICUs (including Nepal), the same kit can run at a US site and an emerging-market site without score drift.

Why now

The source study supplies a newly validated, globally grounded score: development on 2,098,356 patients in 1,319 ICUs across 9 countries, external validation on 1,241,114 patients, day-1 mortality AUROC 0.79 versus 0.77 for SOFA-1, and sequential validity maintained from day 1 to day 7 — precisely the window over which trials measure delta-SOFA endpoints. Sepsis remains one of the largest global causes of infection-related death and organ dysfunction (per the 1990-2021 global burden analysis [1]), so sponsors keep running trials whose endpoints depend on this score; a kit that removes inter-site scoring variability is a bounded, immediately sellable tool for CROs and biotech sponsors.

Written by GLM · 10 Oct 2026

AI assessment

Backed by 2 papers82

A high-utility, narrow-scope tool that solves a specific pain point in clinical trial data integrity by standardizing a newly validated medical score across multicenter sites.

Evidence strength
5/5
The idea is directly supported by a massive, multi-country validation study of SOFA-2 involving over 2 million patients, specifically highlighting its validity from day 1 to day 7.
Market pull
4/5
CROs and pharma sponsors have a high incentive to reduce 'noise' in endpoints to increase the statistical power of expensive sepsis trials.
Novelty & moat
2/5
The idea is a direct application of the 'SOFA-2 Auto-Score' concept, shifting the user from a general ICU clinician to a clinical trial sponsor.
Feasibility
4/5
Building a deterministic scoring engine based on a published formula is straightforward; the primary challenge is EHR integration, which is standard for eSource modules.
Wedge clarity
5/5
The wedge is extremely sharp: a single, standardized score for inclusion and endpoints in sepsis trials.
Simplicity / focus
5/5
It avoids 'platform' creep by focusing on one specific calculation and its audit trail for a single use case.

Scored by Gemma 4 · 10 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • ICON plccompany

    ICON runs late-phase hospital-based critical care studies; standardized SOFA-2 endpoint scoring cuts inter-site variability and data-query burden in trials with organ-dysfunction endpoints.

  • Parexel Internationalcompany

    Parexel's clinical operations serve sponsors with sepsis and ICU trials; a cross-site scoring kit de-risks eligibility and endpoint consistency across global sites.

  • InflaRx AGcompany

    InflaRx develops sepsis therapeutics (vilobelimab); its trial program depends on consistent organ-dysfunction endpoints, and SOFA-2's multi-country validation supports global site selection.

  • Medpacecompany

    Medpace runs hospital-based studies globally, including in emerging markets; a scoring kit validated across resource settings fits its site footprint and endpoint needs.

  • Society of Critical Care Medicineorganization

    SCCM's research networks coordinate multicenter ICU studies; a shared SOFA-2 scoring kit standardizes organ-dysfunction data across participating sites.

Research it builds on

  1. Global, regional, and national sepsis incidence and mortality, 1990–2021: a systematic analysis
    Authia P Gray, Erin Chung, Rebecca L. Hsu et al. · 2025 · 207 citations
    All ideas from this paper →
  2. Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score
    Otavio Ranzani, Mervyn Singer, Jorge I. Salluh et al. · 2025 · 137 citations
    All ideas from this paper →
Leave feedback
feasibility